Abstract A81: Identification of reversion mutation by next-generation sequencing in PARP-inhibitor resistant BRCA2 associated breast cancer: Defects in mis-match repair and acquired chemoresistance in breast cancer

MLA

Serena Wong, et al. “Abstract A81: Identification of Reversion Mutation by next-Generation Sequencing in PARP-Inhibitor Resistant BRCA2 Associated Breast Cancer: Defects in Mis-Match Repair and Acquired Chemoresistance in Breast Cancer.” Molecular Cancer Therapeutics, vol. 14, Dec. 2015, p. A81. EBSCOhost, https://doi.org/10.1158/1535-7163.targ-15-a81.

APA

Serena Wong, Lorna Rodriguez, Deborah Toppmeyer, Kim M. Hirshfield, Jinesh S. Gheeya, Jeremy Tang, Shridar Ganesan, & Joseph Ho. (2015). Abstract A81: Identification of reversion mutation by next-generation sequencing in PARP-inhibitor resistant BRCA2 associated breast cancer: Defects in mis-match repair and acquired chemoresistance in breast cancer. Molecular Cancer Therapeutics, 14, A81. https://doi.org/10.1158/1535-7163.targ-15-a81

Chicago

Serena Wong, Lorna Rodriguez, Deborah Toppmeyer, Kim M. Hirshfield, Jinesh S. Gheeya, Jeremy Tang, Shridar Ganesan, and Joseph Ho. 2015. “Abstract A81: Identification of Reversion Mutation by next-Generation Sequencing in PARP-Inhibitor Resistant BRCA2 Associated Breast Cancer: Defects in Mis-Match Repair and Acquired Chemoresistance in Breast Cancer.” Molecular Cancer Therapeutics 14 (December): A81. doi:10.1158/1535-7163.targ-15-a81.